
|Articles|May 1, 2004
PDT developer seeks FDA approval for its drug for wet form of AMD
Miravant Medical Technologies is asking the FDA to okay a new drug application for marketing approval of its SnET2-PDT as a treatment for patients with wet form of age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Neurotrophic keratitis outcomes improve with early, stage-based care
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Improved grading scales for oncology drugs causing ocular adverse events
4
Alcon raises offer in amended deal to acquire STAAR Surgical
5












































.png)


